Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• MarketBeat consensus: "Moderate Buy" — 18 analysts cover Ultragenyx (1 sell, 2 hold, 14 buy, 1 strong buy) with an average 12‑month target of $60.47 versus the current share price near $22.45, showing wide dispersion in valuation opinions.
• Regulatory catalyst: The FDA accepted the BLA resubmission for UX111 (AAV gene therapy for Sanfilippo syndrome type A), starting a formal review clock and potentially lifting pipeline valuation if the review proceeds smoothly.
• Near‑term risks: The company faces an active securities class‑action solicitation and notable insider selling (109,556 shares sold last quarter), while recent results showed an EPS miss despite 25.5% revenue growth and continued negative profitability metrics.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eighteen ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $60.4706.

A number of equities research analysts have recently weighed in on the stock. Truist Financial upgraded shares of Ultragenyx Pharmaceutical to a "strong-buy" rating in a report on Wednesday, March 25th. Bank of America decreased their target price on shares of Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a "buy" rating on the stock in a research report on Friday, January 2nd. Wells Fargo & Company lowered their price target on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an "overweight" rating for the company in a research note on Tuesday, December 30th. Leerink Partners reduced their price objective on Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an "outperform" rating on the stock in a research note on Tuesday, December 30th. Finally, The Goldman Sachs Group downgraded Ultragenyx Pharmaceutical from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $61.00 to $25.00 in a report on Tuesday, March 24th.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ RARE opened at $22.45 on Friday. The stock has a market cap of $2.21 billion, a price-to-earnings ratio of -3.84 and a beta of 0.25. Ultragenyx Pharmaceutical has a 1-year low of $18.29 and a 1-year high of $42.37. The stock's 50-day moving average is $22.20 and its 200 day moving average is $27.77.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The firm had revenue of $207.28 million during the quarter, compared to analysts' expectations of $199.60 million. During the same period in the prior year, the company earned ($1.39) EPS. The firm's quarterly revenue was up 25.5% compared to the same quarter last year. On average, analysts forecast that Ultragenyx Pharmaceutical will post -5.18 EPS for the current fiscal year.

Ultragenyx Pharmaceutical News Roundup

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: FDA accepts the BLA resubmission for UX111 (AAV gene therapy for Sanfilippo syndrome type A). Acceptance starts a formal FDA review clock and materially improves near‑term clarity on a high‑value gene‑therapy program, which can lift pipeline valuation and upside expectations if the review proceeds smoothly. Read More.
• Neutral Sentiment: CFO Howard Horn disclosed sale of 4,683 shares under a pre‑arranged Rule 10b5‑1 plan; he retains a large position. Because the sale was executed under a 10b5‑1 schedule and his holding remains substantial, markets typically treat this as routine liquidity rather than a signal of undisclosed company problems. Read More.
• Neutral Sentiment: Recent analyst target/coverage updates (mix of cuts and reiterations) keep consensus near a "Moderate Buy" but with wide dispersion in targets, leaving valuation opinion split among investors. (Coverage changes may moderate momentum but are not a single catalytic change.)
• Negative Sentiment: Multiple plaintiff law firms have issued lead‑plaintiff solicitations for a securities class action covering Aug 3, 2023–Dec 26, 2025, with an imminent April 6 deadline. The wave of notices signals an active litigation overhang that can pressure the stock via potential discovery, legal costs, management distraction and settlement risk until the matter is resolved or clarified. Representative notices: Rosen Law Firm and Berger Montague. Read More. Read More.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, EVP Karah Herdman Parschauer sold 8,135 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $185,478.00. Following the completion of the sale, the executive vice president owned 76,346 shares of the company's stock, valued at approximately $1,740,688.80. This represents a 9.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider John Richard Pinion sold 10,029 shares of the firm's stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $228,661.20. Following the completion of the transaction, the insider owned 110,026 shares in the company, valued at $2,508,592.80. This represents a 8.35% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 109,556 shares of company stock worth $2,490,138 over the last quarter. Company insiders own 5.50% of the company's stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Several institutional investors have recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Ultragenyx Pharmaceutical by 14.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company's stock worth $8,414,000 after acquiring an additional 29,984 shares during the last quarter. Creative Planning bought a new position in shares of Ultragenyx Pharmaceutical during the second quarter valued at about $454,000. American Century Companies Inc. purchased a new stake in shares of Ultragenyx Pharmaceutical during the second quarter worth about $366,000. Russell Investments Group Ltd. boosted its holdings in shares of Ultragenyx Pharmaceutical by 15.8% during the second quarter. Russell Investments Group Ltd. now owns 120,195 shares of the biopharmaceutical company's stock worth $4,370,000 after purchasing an additional 16,373 shares during the period. Finally, State Board of Administration of Florida Retirement System grew its stake in shares of Ultragenyx Pharmaceutical by 0.5% in the second quarter. State Board of Administration of Florida Retirement System now owns 93,909 shares of the biopharmaceutical company's stock worth $3,415,000 after purchasing an additional 470 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company's commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.